Skip to main content

The Institute of Translational Research

A doctor in protective glasses holds a test tube up to examine it.
Innovating care through collaborative research
Our researchers take discoveries from "bench to bedside," turning leading-edge science into new therapies for chronic conditions.

Finding new treatments, faster

The Institute of Translational Research (ITR) is accelerating the development of new treatments for a variety of conditions, including brain and nerve diseases like Alzheimer's, ALS, conditions caused by viruses like HIV/AIDS, rare cancers, and mental health conditions.

The ITR collaborates closely with other research groups, companies, government agencies, and the community to turn scientific discoveries into new treatments. This includes conducting early-stage research studies with the help of Northwell's diverse patient population. The ITR also trains the next generation of researchers by providing education and opportunities in translational research to scientists, doctors and students at Northwell Health and around the world.

Making headlines
Douglas Nixon, MD, PhD, will lead the new institute, the sixth to join the Feinstein Institutes.

Our researchers have revealed new gene expression patterns in ancient human endogenous retroviruses (HERVs) that connect gene expression patterns to common mental health disorders, providing a roadmap for future therapeutic research.

Researchers can now identify unique gene expressions to identify new drug targets to treat these disorders.

The Feinstein Institutes—the research institutes of Northwell Health, New York’s largest health care provider—is home to 50 research labs, 3,000 clinical research studies and 5,000 people raising the standard of medical innovation. We make breakthroughs in molecular medicine, genetics, cancer, brain research, mental health, autoimmunity and bioelectronic medicine.